US Patent

US9198905 — Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects

Method of Use · Assigned to Antecip Bioventures II LLC · Expires 2034-11-05 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of reducing dextrorphan plasma levels by co-administering hydroxybupropion and dextromethorphan to a human being.

USPTO Abstract

This disclosure relates to methods of decreasing dextrorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3419`	—

Patent Metadata

Patent number: US9198905
Jurisdiction: US
Classification: Method of Use
Expires: 2034-11-05
Drug substance claim: No
Drug product claim: No
Assignee: Antecip Bioventures II LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.